Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...
The bank, which cannot be named for reasons of confidentiality, has awarded the deal on a “warm” basis, meaning that Vertex is ready to deploy its people and systems within 60 days if invoked.
Keeping the purpose of the statute in mind, section 165.540(1)(c) is exceptionally well tailored ... Time, Inc. (9th Cir. 1971) (rejecting the argument that the First Amendment accorded ...
The VOP request was granted after a thorough review from the FCA, which scrutinised Vertex’s advice model, as well as looking at its overall competence, systems and controls. Robert Coyle ...
The Duchess of Sussex's pals are counting down to the debut of "With Love, Meghan" on Jan. 15 Janine Henni is a Royals Staff Writer for PEOPLE Digital, covering modern monarchies and the world's ...
Roche is spending $80 million upfront on a new product from existing partner Innovent Biologics. The DLL3-targeting candidate for small cell lung cancer is the … ...
Vertex Pharmaceuticals' suzetrigine showed lackluster Phase II results, but I still see potential in the non-addictive pain management market given the opioid crisis. Vertex's dominance in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback